# Halper Sadeh Investigates Whether Aytu BioPharma's $2.70-Per-Share Rosemont Sale Is Fair

> Halper Sadeh LLC is investigating Aytu BioPharma's $2.70-per-share sale to Rosemont Pharmaceuticals over whether shareholders are getting a fair price.

- Published: 2026-11-16T23:57:12+00:00
- Section: Legal & Disputes
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-16/halper-sadeh-aytu-biopharma-rosemont-sale
- Source: [Business Wire](https://www.businesswire.com/news/home/20261116954941/en/)

## Key takeaways

- Halper Sadeh LLC is investigating Aytu BioPharma's proposed sale to Rosemont Pharmaceuticals Holdings at $2.70 per share.
- The firm questions whether Aytu's board obtained the best price, ran a conflict-free sales process and disclosed all material information.
- Halper Sadeh may seek increased consideration, additional disclosures or other relief on a contingent fee basis.

[Halper Sadeh](https://akta.pro/company-profiles/0003mmi/halper-sadeh) LLC is investigating Aytu BioPharma, Inc.'s proposed sale to [Rosemont Pharmaceuticals](https://akta.pro/company-profiles/0006pp1/rosemont-pharmaceuticals) Holdings, Inc. at $2.70 per share, the investor rights law firm said in a [Business Wire](https://www.businesswire.com/news/home/20261116954941/en/) announcement dated November 16, 2026. The firm said it may seek increased consideration, additional disclosures or other relief for shareholders.

## Halper Sadeh's Questions About the Aytu Sale

The investigation concerns whether [Aytu BioPharma](https://akta.pro/company-profiles/0000zpq/aytu-biopharma) and its board violated federal securities laws or breached fiduciary duties by failing to obtain the best possible price for shareholders, conduct a fair sales process free of conflicts of interest, and disclose all material information shareholders need to evaluate the transaction. Halper Sadeh said insiders may stand to receive substantial financial benefits not available to ordinary shareholders, and that the proposed transaction may contain terms that could limit superior competing offers. The firm said shareholders can contact Daniel Sadeh or Zachary Halper at no cost or obligation, and that it would handle any matter on a contingent fee basis, with clients not responsible for out-of-pocket legal fees or expenses. Aytu BioPharma is a Nasdaq-listed company that reported fiscal 2026 net revenue of $57.6 million, driven by ADHD and pediatric products and initial EXXUA sales, according to Ticker Report.

## Halper Sadeh's Record on Deal Reviews

akta.pro [Company records](https://akta.pro/company-data) show Halper Sadeh was founded in New York in 2015 as a specialized investor rights law firm with a contingency-fee model for securities fraud and corporate misconduct litigation. The same records list recoveries including $20 million in In re Galena Biopharma, Inc., Securities Litigation and $23.5 million in Thomas v. Magnachip Semiconductor Corp. The firm's leadership includes founding partners Zachary Halper and Daniel Sadeh.

## Earlier Halper Sadeh Investigations

Halper Sadeh announced on November 11, 2026 that it was investigating DoubleDown, Greenfire, Penske Automotive and Ultralife for potential securities law violations and fiduciary breaches, according to GlobeNewswire. On November 10, 2026, the firm said it was investigating Array Technologies, Range Resources, Surgery Partners and Lumentum Holdings on the same grounds, GlobeNewswire reported. On September 8, 2026, FinancialContent Business Page reported the firm was investigating Bio-Techne's sale to Merck, Colony Bankcorp's merger with First Reliance and Auddia's merger with Thramann for potential securities law violations.

## What Comes Next for Aytu Shareholders

Aytu BioPharma was expected to report Q1 2027 earnings after market close on November 12, 2026, with analysts projecting a loss of $0.2567 per share and revenue of $13.27 million, according to American Banking and Market News.

## Companies in this story

- [Halper Sadeh company profile](https://akta.pro/company-profiles/0003mmi/halper-sadeh) · website: https://halpersadeh.com
- [Aytu BioPharma company profile](https://akta.pro/company-profiles/0000zpq/aytu-biopharma) · website: http://aytubio.com
- [Rosemont Pharmaceuticals company profile](https://akta.pro/company-profiles/0006pp1/rosemont-pharmaceuticals) · website: https://www.rosemontpharma.com

---
News for Agent · https://newsforagent.com/llms.txt
